GLOW: Mechanism of Action
Mechanism of Action β Three-Component Series
1. GHK-Cu (50 mg, 71.4% of mass) β Copper Delivery & Gene Modulation
The largest component, GHK-Cu, is the endogenous tripeptide Gly-His-Lys chelated to a Cu(II) ion. It "redox silences" copper to prevent Fenton-reaction toxicity while delivering Cu into cells for use by lysyl oxidase (collagen crosslinking) and Cu/Zn-SOD. Connectivity Map analysis confirmed GHK modulates >4,000 genes, suppressing inflammatory/metastatic signatures and activating repair programs.[9][10] Stimulates collagen I/III, elastin, GAGs, and decorin synthesis with biphasic dose-response peaking near 10β»βΉ M.[11]
2. BPC-157 (10 mg, 14.3% of mass) β VEGFR2-Akt-eNOS Angiogenic Cascade
BPC-157 binds and internalizes VEGFR2 on endothelial cells, triggering Akt phosphorylation and eNOS activation, yielding nitric oxide production essential for vascular repair (129β152% increased angiogenesis in chick chorioallantoic membrane and rat hind-limb ischemia models).[5] BPC-157 also activates the FAK-paxillin pathway and upregulates growth-hormone-receptor expression on tendon fibroblasts.[12]
3. TB-500 (10 mg, 14.3% of mass) β G-Actin Sequestration & Cell Migration
The LKKTETQ motif binds monomeric G-actin in a 1:1 complex, regulating polymerization into filamentous actin and enabling cytoskeletal reorganization required for cell motility.[6] TB-500 also engages F1-F0 ATP synthase on endothelial cells (KD β 12 nM), forms a complex with integrin-linked kinase (ILK) and PINCH that activates Akt2, and upregulates MMP-2/MMP-9 to facilitate basement-membrane remodeling during angiogenesis.[13][14] Note: TB-500 lacks the N-terminal Ac-SDKP tetrapeptide of full-length TΞ²4 and therefore does not contribute the anti-fibrotic TGF-Ξ²-modulating activity of the parent molecule.[15]
Combined Mechanistic Rationale
| Repair Axis | Primary Driver | Molecular Target |
|---|---|---|
| ECM synthesis & gene modulation | GHK-Cu | Cu(II) delivery; ~31% genome modulated |
| Angiogenesis & NO signaling | BPC-157 | VEGFR2 β Akt β eNOS |
| Cell migration & cytoskeleton | TB-500 | G-actin 1:1 binding; ILK-PINCH-Akt2 |
| Antioxidant defense | GHK-Cu, TB-500 | Nrf2/Keap1; SOD upregulation |
| Anti-inflammatory | All three | NF-ΞΊB p65 phosphorylation blockade |
No published peer-reviewed pharmacokinetic or pharmacodynamic studies have evaluated the 50/10/10 blend as a single co-administered formulation. All mechanistic content is extrapolated from individual-component literature.
βPreclinical Research Summary (Component-Level) No peer-reviewed studies have evaluated the GLOW 50/10/10 blend as a co-administered formulation.β
References
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987.
- Sikiric P, Hahm KB, Blagaic AB, Tvrdeic A, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153-167.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin Ξ²4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
- Pickart L, Vasquez-Soltero JM, Margolina A. Cosmetics. 2015;2(3):236-247.
- Hsieh MJ, et al. Journal of Molecular Medicine. 2017;95(3):323-333.
- Xing Y, Ye Y, Zuo H, Li Y. Progress on the Function and Application of Thymosin Ξ²4. Frontiers in Endocrinology. 2021;12:767785.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding. FDA.gov. Updated 2023.
- World Anti-Doping Agency. The 2025 Prohibited List. WADA. January 1, 2025.
- Pickart L, Vasquez-Soltero JM, Margolina A. BioMed Research International. 2014;2014:151479.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways. BioMed Research International. 2015;2015:648108.
- Maquart FX, Pickart L, et al. Stimulation of collagen synthesis by GHK-Cu. FEBS Letters. 1988;238(2):343-346.
- Chang CH, et al. BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(12):19066-19077.
- Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature. 2004;432(7016):466-472.
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta 4. The FASEB Journal. 2010;24(7):2144-2151.
- Bock-Marquette I, et al. International Immunopharmacology. 2023;116:109741.
- Canapp SO Jr, et al. Veterinary Surgery. 2003;32(6):515-523.
- Philp D, et al. Thymosin Ξ²4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair. Wound Repair and Regeneration. 2003;11(1):19-24.
- Staresinic M, et al. BPC 157 accelerates healing of transected rat Achilles tendon. Journal of Orthopaedic Research. 2003;21(6):976-983.
- Badenhorst T, et al. Effects of GHK-Cu on MMP and TIMP Expression. Journal of Aging Science. 2016;4(3):166.
- Smart N, et al. Nature. 2007;445(7124):177-182.
- Kuceki G, et al. JAAD International. 2025;20:38-40.
- Goldstein AL, et al. Thymosin Ξ²4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9):421-429.
- Sever M, et al. BPC 157 counteracts liver fibrosis. Journal of Physiology and Pharmacology. 2019;70(3):391-400.
- Shah R, et al. Oxidative Medicine and Cellular Longevity. 2018;2018:9630175.
- Sosne G, Dunn SP, Kim C. Cornea. 2015;34(5):491-496.
Related Research Questions
Related research
Want the complete research review?
Browse the Peptide Research LibraryβFOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.